Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired hypothalamic ...
Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare ...
Rhythm Pharmaceuticals, Raymond A. Wood Fountain announce research collab
Rhythm Pharmaceuticals (RYTM) and the Raymond A. Wood Foundation announced a new research collaboration to study the impact of fatigue on ...
Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration
New registry study to focus on impact of fatigue in people with craniopharyngiomaBOSTON, March 18, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage ...
Mum 'missed' son's first year as blurred vision while pregnant was due to brain tumour
A woman has shared her horrifying ordeal after her "blurry vision" during pregnancy was actually caused by a golf ball-sized ...
I was diagnosed with a brain tumour after getting blurry vision
Abbie Keet, 24, developed a golf ball-sized tumour and started having eye problems when she was pregnant with her first child ...
Frontiers19d
Neoadjuvant B-RAF and MEK Inhibitor Targeted Therapy for Adult Papillary Craniopharyngiomas: A New Treatment Paradigm
Improvements in knowledge of craniopharyngioma molecular biology may offer the possibility of safe and effective medical neoadjuvant treatments in a subset of patients harboring papillary subtype ...